UTU is a company dedicated to building the trust infrastructure for the evolving web 3.0. They aim to facilitate safer and more reliable interactions between users and platforms by utilizing a decentralized reputation and reviews protocol. This protocol involves a non-tradable reputation token (UTT) that users can stake to endorse others, leading to positive outcomes. UTU's focus initially lies in Web3 and DeFi apps, where they provide AI-powered tools to curate trust signals and help users engage confidently in various online activities. They offer a range of products, including the UTU Trust Token, Browser Extension, and Trust API/SDK, all aimed at enhancing trust and security in digital interactions.
days to go:
Extended
investment:
£150,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Goldilock empowers remote, instant control of physical connections and disconnections for assets, devices, data, and network segments – all without internet dependency. Addressing the vulnerabilities of the Cloud and emerging technologies, Goldilock provides a solution that leverages physical disconnection, offering heightened cybersecurity. With the endorsement of experts like Gregory Akers from CISCO, Goldilock excels in securing IP-based network components, achieving unmatched security through on-demand isolation or connection that remains unseen by cyber threats.
days to go:
Expired
investment:
£200,000
Business Finance Market (BFM) is a financial technology platform that stimulates the market towards Small and Medium Enterprises (SMEs) lending via data in the UK. BFM claims that SMEs are gradually being excluded from mainstream banking. The company cites that in 1988, 40% of all bank lending went to SMEs. BFM points out that lending today is closer to 4% with an estimated £22 billion funding gap to the 5.9 million UK SMEs. BFM asserts that almost 90% of SME loan applications are stuck due to a lack of choice and transparency when it comes to securing finance. BFM aspires to solve this dilemma. It states that its technology allows SMEs to experience quicker finance decisions based on true addressable market access and allows lenders and intermediaries access to its platform to help manage the end-to-end application process, improve deal flow, and deliver faster credit decisions. BFM intends to exit via a trade sale within the financial sector.
days to go:
Expired
investment:
Withheld
Intelligent Health aim to get the whole community active by providing games and incentives such as ''beat the street''. By providing schools and communities with friendly competition to walk and cycle more by tapping their cards on ''beat boxes'', and with prizes and league tables on offer, Intelligent health are bringing communities together.
days to go:
Expired
investment:
£700,000
Liquid supplements are a faster acting and a more efficient way for the body to absorb key active ingredients than taking pills. Our scientists have developed formulations involving leading active ingredients such as collagen in order to create the perfect wellness solution in every bottle. Each LQ bottle is packed full of 9 or more active ingredients all in one easy to drink, daily 50 m bottle.
days to go:
Expired
investment:
£355,000
Simply get results limited are a universal data analytics solution, improving financial performance through people. They have established a client portfolio of household names and are profitable with over £400k of revenue. They save organisations tens of millions of pounds using their proprietary software and unique algorithms to find patterns and trends to present unseen opportunities.
days to go:
Expired
investment:
£205,000
Studio Pictures Limited is a UK based production company that specialises in the development of high-quality British film and TV projects. The company's interest predominantly lies within the British film and television industry that can be created within budget ranging from £1 million - £15 million. The company has established relationships with studio houses such as Warner Bros., Sony Pictures and Lionsgate and aims to build upon projects that can be made into a franchise. Their production, A Steet Cat Named Bob, went on to be distributed by Sony Pictures in the UK and had a Royal Premiere in London. Studio Pictures Limited will consider putting up to a maximum of 20% of the budget for each project as equity, on a case by case basis, subject to company reserves. With the proceeds, the company will grow and scale the business. It will become a tenant at Twickenham Studios in West London and look to profitable emerging markets, i.e. streaming, animation and interactive movies to become one of the leading UK production companies.
days to go:
Expired
investment:
Withheld
HeadBox are trying to make the process of booking the perfect space for your client or work based event simpler. HeadBox are looking to do this by using their efficient platform to connect guests and hosts directly. Hosts are able to list their space on the platform and guests are able to browse the site to find their ideal space.
days to go:
Expired
investment:
£762,000
Ceryx Medical is a medical technological entity that is developing bioelectronics based on a unique, patent-protected, chip technology that can mimic nerve centres within the body called Central Pattern Generators (CPGs). CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate, and even walking. The Ceryx system resembles a traditional cardiac pacing device that holds a lot of promise in potentially alleviating incidences of heart failure leading to a therapeutic effect on patient health. In the UK, this is a day surgery procedure under local anaesthetic with a basic system costing around £3500. The device, therefore, offers a cost-effective, single procedure solution for this currently intractable disease. Treatment expenditures on heart failure cases in the EU amount to almost £35 billion. The Ceryx system is a potential disruptor in this segment and offers multiple potential applications. The company is targeting £500,000 as part of £1 million round. With the investment, the company aims to produce a data package that mimics those used to support 510k/NDA applications, as mandated by the US Food and Drug Administration (FDA), for current devices and drugs used to treat heart failure.
days to go:
Expired
investment:
Withheld
